Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Camurati-Engelmann Syndrome 1

Interventions

Temozolomide 115Radiotherapy 63Magnetic Resonance Spectroscopy 30Carboplatin 30Bevacizumab 30Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 18Lomustine 17Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Astrocytoma × Trabedersen × Clear all
NCT00761280 2014-11-14

SAPPHIRE

Isarna Therapeutics GmbH

Phase 3 Terminated
27 enrolled 28 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Neoplasms

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Isarna Therapeutics GmbH

Phase 2 Completed
141 enrolled
CNS

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡